Plain-English translation of NCT04376866 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called combined with radiation therapy and chemotherapy to treat nasopharyngeal cancer (a type of throat cancer) that has come back after previous treatment. is an immunotherapy drug that helps your immune system fight cancer cells. Researchers want to see if adding this medication to standard treatment works better than radiation and chemotherapy alone.
About 1 in 10 people with nasopharyngeal cancer experience recurrence after their initial treatment, and standard retreatment has poor results because cancer cells can become resistant to radiation. This trial exists to find better options that improve survival and reduce side effects for people facing this difficult situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one receiving the new medication () plus radiation and chemotherapy, or the other receiving just radiation and chemotherapy. The treatment involves receiving chemotherapy drugs and radiation therapy over several weeks, with the medication group also receiving additional doses of afterward. You will have regular visits for treatment and monitoring, including blood tests and imaging scans to check how well the treatment is working and track any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Cancer Hospital of Guangxi Medical University
Enrollment target
~204 participants
Started
June 2020
Primary completion
April 2023
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Song Qu, PhD
Principal Investigator
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.